Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Locally Recurrent Skin Squamous Cell Carcinoma 1Colonic Neoplasms 1

Interventions

Fluorouracil 87Leucovorin 78Oxaliplatin 77Irinotecan 76Bevacizumab 50Cetuximab 42Capecitabine 42Panitumumab 17Folfox protocol 16Floxuridine 11Chemotherapy, Adjuvant 11regorafenib 10IFL protocol 10Nivolumab 9Drug Therapy 9trifluridine tipiracil drug combination 8Surgical Procedures, Operative 8Neoadjuvant Therapy 8sargramostim 7pembrolizumab 7XELOX 7Specimen Handling 7Biopsy 7Trastuzumab 6Radiotherapy 6Magnetic Resonance Spectroscopy 6HMPL-013 6tislelizumab 5encorafenib 5Trifluridine 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Colonic Neoplasms × (225)Ac-DOTA-c(RGDyK) × Clear all
NCT05308446 2026-06-03

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

National Cancer Institute (NCI)

Phase 2 Active not recruiting
86 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡